[The Diabetic Retinopathy Candesartan Trials (DIRECT) programme]

Nihon Rinsho. 2005 Jun:63 Suppl 6:297-301.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Albuminuria / drug therapy
  • Angiotensin II / physiology
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Animals
  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use*
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use*
  • Biphenyl Compounds
  • Diabetic Retinopathy / diagnosis
  • Diabetic Retinopathy / etiology
  • Diabetic Retinopathy / prevention & control*
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Randomized Controlled Trials as Topic
  • Receptors, Vascular Endothelial Growth Factor / metabolism
  • Renin-Angiotensin System / physiology
  • Retina / metabolism
  • Risk Factors
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Benzimidazoles
  • Biphenyl Compounds
  • Tetrazoles
  • Vascular Endothelial Growth Factor A
  • Angiotensin II
  • Receptors, Vascular Endothelial Growth Factor
  • candesartan